•
Mar 31, 2023

Arcellx Q1 2023 Earnings Report

Arcellx reported financial results for the first quarter ended March 31, 2023.

Key Takeaways

Arcellx reported collaboration revenue of $17.9 million due to the Kite partnership, and anticipates current funds to support operations through the first half of 2025.

Closed Kite partnership in the first quarter.

Well capitalized to fund operations through the first half of 2025.

Focused on completing enrollment of iMMagine-1.

Initiating iMMagine-2 in earlier multiple myeloma lines.

Total Revenue
$17.9M
EPS
-$0.58
Previous year: -$1.56
-62.8%
Gross Profit
$17.2M
Cash and Equivalents
$534M
Previous year: $127M
+319.6%
Free Cash Flow
$181M
Previous year: -$33.1M
-647.8%
Total Assets
$623M
Previous year: $247M
+152.2%

Arcellx

Arcellx

Forward Guidance

Arcellx expects that the cash, cash equivalents, and marketable securities on hand, will fund its operations through BLA filing of CART-ddBCMA planned for the first half of 2025